Project Description

Mimetas

MIMETAS (Leiden, the Netherlands, Gaithersburg, USA, Tokyo, Japan) provides organ-on-a-chip products for compound testing, screening and fundamental research. Its flagship product, the OrganoPlate®, supports 3D cell culture under continuous perfusion, with membrane-free co-culture and epithelial and endothelial tubules. The company develops and validates customized disease, toxicology and transport models and ultimately will make its technology available for personalized therapy selection. MIMETAS has developed models for the kidney, liver, gut, brain and a range of oncological applications, that offer better predictivity towards human physiology as compared to laboratory animals and conventional cell culture models. Since its commercial launch in 2014, MIMETAS has grown its customer base to half of the global top-50 pharmaceutical companies, in addition to chemical, food and consumer goods companies. The fast market acceptance of the OrganoPlate® is driven by its unsurpassed ease-of-use and throughput, in combination with complex human biology and disease relevance.

MIMETAS will conduct morphofunctional in vitro studies on 3D cultures using their ‘Organ-on-a-Chip’ platform, as well as contribute to signature validation.

Mimetas logo
Remko van Vught
Remko van Vught
Director of Business Development
Henriette Lanz
Henriette Lanz
Director of Model Development
Tania Fowke
Tania Fowke
Scientist, Model Development